Wright Medical shares rise on Q2 earnings Beat

Shares in Wright Medical (NSDQ:WMGI) rose today in pre-market trading after the medical device maker beat expectations on Wall Street with its second quarter results. The Amsterdam-based company posted losses of $67.7 million, or 64¢ per share, on sales of $205.4 million for the three months ended July 1, seeing losses grow 64.5% while sales grew 14.3% compared with the same period last year. Adjusted to exclude one-time items, losses per share were 3¢, just ahead of the 6¢ loss-per-share consensus on The Street, where analysts were looking for sales of $196.8 million, which the company also topped. “We produced outstanding results across the board in the second quarter, including 13% constant currency net sales growth, an estimated 370 basis point increase versus the first quarter of 2018, and we exited the quarter on a strong, positive trajectory, which we expect to continue throughout the remainder of 2018.  These results represent another strong performance in our U.S. upper extremities business, which grew 22% in the second quarter, driven by 24% growth in our U.S. shoulder business.  We anticipate that continued penetration of our Simpliciti shoulder system, our ongoing Perform reversed launch and accelerating adoption of our Blueprint enabling technology will continue to drive market-leading shoulder sales growth in 2018,” prez &CEO Robert Palmisano said in a press release. “Our U.S. lower extremities growth rate acce...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat wrightmedical Source Type: news

Related Links:

Authors: Chang KY, Hsu WK Abstract As the use of minimally invasive spine (MIS) fusion approaches continues to grow, increased scrutiny is being placed on its outcomes and efficacies against traditional open fusion surgeries. While there are many factors that contribute to the success of achieving spinal arthrodesis, selecting the optimal fusion biologic remains a top priority. With an ever-expanding market of bone graft substitutes, it is important to evaluate each of their use as it pertains to MIS techniques. This review will summarize the important characteristics and properties of various spinal biologics used...
Source: Minimally Invasive Surgery - Category: Surgery Tags: Minim Invasive Surg Source Type: research
AbstractAllograft lithiasis is a rare urologic complication of renal transplantation (RT). Our aim is to present our experience with minimally invasive surgical treatment of allograft lithiasis in our series of live-donor renal transplant recipients. In a retrospective analysis of 3758 consecutive live-donor RTs performed in our center between November 2009 and January 2017, the results of minimally invasive surgery for the treatment of renal graft lithiasis diagnosed at follow-up were evaluated. Twenty-two (0.58%) patients underwent minimally invasive surgery for renal graft lithiasis. The mean age was 41.6 years, and dur...
Source: Urolithiasis - Category: Urology & Nephrology Source Type: research
ConclusionTERT is a technically demanding procedure that closely resemble open technique while imparting the benefits of minimally invasive surgery to the patient.
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
Israel’s Bonus Biogroup (TLV:BONS) said today that it successfully injected its lab-grown, semi-liquid bone graft into the jaws of 11 people in an early stage clinical trial evaluating bone loss repair. The company is presenting its results at the International Conference on Oral & Maxillofacial Surgery in Spain today. The material is grown in a lab from a patient’s  own fat cells and then injected into the voids of problematic bones in the jaw. Over the course of a few months, the material hardens and merges with existing bones to fill out the jaw. The transplant “was 100% successful in al...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Materials Testing Orthopedics Research & Development Stem Cells Bonus Biogroup Source Type: news
CONCLUSION: This review highlights the high risk of neural injury (up to 75% for sensory, 33.6% for motor, and an overall plexus injury rate of 13.28%) utilizing the XLIF and other similar lateral lumbar approaches. With such extensive neurological injuries, is the XLIF really safe, and should it still be performed? PMID: 27843679 [PubMed - in process]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Abstract: The deep layers of the nasoethmoid region comprise a thin-walled lacrimal bone, a paper-thin ethmoid plate, and ethmoidal cells, forming an extremely fragile and easily crushed structure. In a nasoethmoid complex fracture where the support structure itself is destroyed, epithesis and immobilization are difficult and can lead to residual saddle nose deformities. Therefore, bone grafts are often necessary at a later date. Recently, the authors occasionally see reports of nasoethmoid complex fractures that are treated with Halo distraction devices. Advantages of this device are that it applies constant traction to m...
Source: Journal of Craniofacial Surgery - Category: Surgery Tags: Technical Strategies Source Type: research
CONCLUSION: In cases of low-volume intraoperative CSF leak, layered skull base repair with avascular free grafts was an acceptable alternative to the nasoseptal flap, which may reduce prolonged sinonasal healing and donor-site morbidities. PMID: 27657903 [PubMed - in process]
Source: American Journal of Rhinology and Allergy - Category: ENT & OMF Authors: Tags: Am J Rhinol Allergy Source Type: research
Conclusions: In our experience, curettage of ACT/CS1 in the long bones with adjuvant phenolization is safe, even with large tumors of up to 100 cm3. Most worrisome is the risk of fracture, which occurred in 10.2% of our patients. Considering the relatively mild behavior of ACT/CS1, less aggressive treatment, by observation or by minimally invasive surgery, could be the next step that should be evaluated prospectively. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Source: JBJS - Category: Orthopaedics Authors: Tags: Oncology Scientific Articles Source Type: research
This study quantified how the setting of a material reduces the accessibility of the release media to the material, thus preventing drug release. A shift in the drug release pattern was observed, from a burst-release for fresh cements to a sustained release for pre-set cements. Graphical abstract
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Publication date: February 2015 Source:Journal of Clinical Neuroscience, Volume 22, Issue 2 Author(s): Adrian J. Talia , Michael L. Wong , Hui C. Lau , Andrew H. Kaye This review will outline the history of spinal fusion. It will compare the different approaches currently in use for interbody fusion. A comparison of the techniques, including minimally invasive surgery and graft options will be included. Lumbar interbody fusion is a commonly performed surgical procedure for a variety of spinal disorders, especially degenerative disease. Currently this procedure is performed using anterior, lateral, transforaminal and post...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
More News: Bone Graft | Medical Devices | Minimally Invasive Surgery | Profits and Losses